Amgen reports landmark survival data; Brazil court orders Meta to halt election interference
FROM THE WIRE · THESTOCKMARKETWATCH.COM
Amgen (AMGN) released landmark results from its Phase 3 DeLLphi-305 trial today, showing that Imdelltra (tarlatamab-dlle) significantly improves survival
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAmgen's Phase 3 results can affect the stock, while the Meta order is a separate political issue.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Amgen released Phase 3 DeLLphi-305 trial results.
- 02Imdelltra (tarlatamab-dlle) significantly improves survival.
- 03A Brazilian court ordered Meta to halt election interference.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets